Published in
Springer Nature [academic journals on nature.com], Leukemia, 2023
DOI: 10.1038/s41375-023-02073-x
Links
Tools
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML
Journal article published in 2023 by
Guillermo Garcia-Manero 
,
Nikolai A. Podoltsev ,
Megan Othus ,
John M. Pagel ,
Jerald P. Radich,
Min Fang,
David A. Rizzieri ,
Guido Marcucci ,
Stephen A. Strickland ,
Mark R. Litzow ,
M. Lynn Savoie,
Bruno C. Medeiros,
Mikkael A. Sekeres ,
Tara L. Lin ,
Geoffrey L. Uy
and other authors.
,
Nikolai A. Podoltsev ,
Megan Othus ,
John M. Pagel ,
Jerald P. Radich,
Min Fang,
David A. Rizzieri ,
Guido Marcucci ,
Stephen A. Strickland ,
Mark R. Litzow ,
M. Lynn Savoie,
Bruno C. Medeiros,
Mikkael A. Sekeres ,
Tara L. Lin ,
Geoffrey L. Uy
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 